Strong opioids for cancer pain

McQuay H , Moore A. Need for rigorous assessment of palliative care. BMJ 1994; 309: 1315–16

Brescia FJ , Portenoy RK , Ryan M , Krasnoff L , Gray G. Pain, opioid use, and survival in hospitalized patients with advanced cancer. J Clin Oncol 1992; 10: 49–55

Collin E , Poulain P , Gauvain-Piquard A , Petit G , Pichard-Leandri E. Is disease progression the major factor in morphine ‘tolerance’ in cancer pain treatment? Pain 1993; 55: 319–26

Culpepper-Morgan JA. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 1992; 52: 90–5

O'Neill WM , Hanks GW , Simpson P , Fallon MT , Jenkins E , Wesnes K. The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo. Pain 2000; 85: 209–15

Vainio A , Ollila J , Matikainen E , Rosenberg P , Kalso E. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 1995; 345: 667–70

Daeninck PJ , Bruera E. Opioid use in cancer pain. Is a more liberal approach enhancing toxicity? Acta Anaesthesiol Scand 1999; 43: 924–38

Mercadante S. The role of morphine glucuronides in cancer pain. Palliative Med 1999; 13: 95–104

Bartlett SE , Dodd PR , Smith MT. Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites. Pharmacol Toxicol 1994; 75: 73–81

Potter JM , Reid DB , Shaw RJ , Hackett P , Hickman PE. Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs. BMJ 1989; 299: 150–3

Heger S , Maier C , Otter K , Helwig U , Suttorp M. Morphine induced allodynia in a child with brain tumour. BMJ 1999; 319: 627–9

Halliday AJ , Bartlett SE , Colditz P , Smith MT. Brain region-specific studies of the excitatory behavioral effects of morphine-3-glucuronide. Life Sci 1999; 65: 225–36

Sullivan AF , McQuay HJ , Bailey D , Dickenson AH. The spinal antinociceptive actions of morphine metabolites morphine-6-glucuronide and morphine in the rat. Brain Res 1989; 482: 219–24

Schuller AG , King M , Zhang J Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MORI. Nat Neurosci 1999; 2: 151–6

Rossi GC , Brown GP , Leventhal L , Yang K , Pasternak GW. Novel receptor mechanisms for heroin and morphine-6-glucuronide induced analgesia. Neurosci Lett 1996; 216: 1–4

Tiseo PJ , Thaler HT , Lapin J , Inturrisci CE , Portenoy RK , Foley KM. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995; 61: 47–54

Morley JS , Watt J , Wells JC , McKibbin PE , Miles JB. Paradoxical and other pains uncontrolled by morphine. In: Gebhart GK , Hammond DL , Jensen TS , eds. Proceedings of the Seventh World Congress on Pain (Progress in Pain Research and Management Vol 2). Seattle, WA: IASP Press. 1994: 621–30

Smith MT , Wright A , Williams B , Stuart G , Gramond T. Cerebrospinal fluid and plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in patients before and after initiation of intracerebroventricular morphine for cancer pain management. Anesth Analg 1999; 88: 109–16

Hewett K , Dickenson AH , McQuay H. Lack of effect of morphine-3-glucuronide on the spinal antinociceptive actions of morphine in the rat: an electrophysiological study. Pain 1993; 52: 659–63

Faura CC , Moore A , Horga JF , Hand C , McQuay H. Morphine and M-6-G plasma concentrations and effect in cancer pain. J Pain Symptom Management 1996; 11: 95–102

Portenoy RK , Foley KM , Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990; 43: 273–86

Grond S , Radbruch L , Meuser T , Sabatowski R , Loick G , Lehmann A. Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain 1999; 79: 15–20

Dickenson AH. NMD A receptor antagonists: interactions with opioids. Acta Anaesthesiol Scand 1997; 41: 112–15

Besse D , Lombard MC , Zajac JM. Pre- and postsynaptic distribution of mu, delta and kappa opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord: a quantitative autoradiographic study. Brain Res 1990; 521: 15–22

Zhang X , Dangerlind Å , Elde RP Marked increase in cholecystokinin B receptor mesenger RNA levels in rat dorsal root ganglia after peripheral axotomy. Neuroscience 1993; 57: 227–33

Dertwinkel R , Zenz M , Strumpf M , Donner B. Clinical status of opioid tolerance in long-term therapy of chronic noncancer pain. In: Kalso E , McQuay H , Wiesenfeld-Hallin Z , eds. Opioid Sensitivity of Chronic Noncancer Pain. Seattle: IASP Press, 1999: 129–41

Dickenson AH. Neurophysiology of opioid poorly responsive pain. Cancer Surv 1994; 21: 5–16

Antunes Bras JM , Benoliel JJ , Bourgoin S Effects of peripheral axotomy on cholecystokinin neurotransmission in the rat spinal cord. J Neurochem 1999; 72: 858–67

Mao J , Price DD , Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view on their possible interactions. Pain 1995; 62: 259–74

Budd K , Monoamine function and analgesia. Pain Rev 1994; 1: 3–8

Mucci-LoRusso P , Berman BS , Silberstein PT Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 1998; 2: 239–49

Maddocks I , Somogyi A , Abbott F , Hayball P , Parker D. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Management 1996; 12: 182–9

Heiskanen T , Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 1997; 73: 37–45

Ahmedzai S , Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Management 1997; 13: 254–61

Portenoy RK , Payne R , Coluzzi P Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999; 79: 303–12

Galer BS , Coyle N , Pasternak GW , Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain 1992; 49: 87–91

Bruera E , Pereira J , Watanabe S , Belzile M , Kuehn N , Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone and morphine. Cancer 1996; 78: 852–7

de Stoutz ND , Bruera E , Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Management 1995;10: 378–84

Hawley P , Forbes K , Hanks GW. Opioids, confusion and opioid rotation. Palliative Med 1998; 12: 63–4

Dickenson AH. Pain and analgesia: new light on mechanism and therapy. CME Bulletin Palliative Med 1999; 1(4): 98–103

Chapman V , Dickenson AH. The combination of NMDA receptor antagonists and morphine produces profound antinociception in the rat dorsal horn. Brain Res 1992; 573: 321–3

Taiwo YO , Fabian A , Pazoles CJ , Fields HL. Potentiation of morphine antinociception by monoamine reuptake inhibitors in the rat spinal cord. Pain 1985; 21: 329–37

Carpenter K , Chapman V , Dickenson AH. Neuronal inhibitory effects of methadone are predominantly opioid receptor mediated in the rat spinal cord in vivo. Europ J Pain 2000; 4: 19–26

Katz N. MorphiDex (double-blind, multiple-dose studies in chronic pain patients). J Pain Symptom Management 2000; 19(suppl): 37–41

McQuay H , Carroll D , Jadad AR Dextromethorphan for the treatment of neuropathic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design. Pain 1994; 59: 127–33

Finlay I. Ketamine and its role in cancer pain. Pain Rev 1999; 6: 303–13

Makin MK , Coackley A , Duckitt H , Fleming J , Skinner J , Ellershaw JE. A report of adverse events occurring during methadone therapy for chronic cancer pain. Proc Palliative Care Congress, Warwick, 27-29 March, 2000

Zenz M , Willweber-Strumpf A. Opiophobia and cancer pain in Europe. Lancet 1993; 341: 1075–6